| 247 | spe-9(hc88)_15_16_81 | spe-9(hc88)_23_7_105 | - | — | 122.252010724 | — | — | <0.0001 | 15°C vs. 23°C | — | — |
| 238 | Oregon_minocycline_15_41 | Oregon_control_7_32 | - | Minocycline treatment | 114.285714286 | — | 28.125 | <0.0002 | — | male | — |
| 327 | Wistar_62_42_66_6 | Wistar_29_22_38_6 | MUT | C60-olive oil treatment | 113.793103448 | 90.9090909091 | 73.6842105263 | — | — | male | — |
| 249 | spe-9(hc88)_15_15_90 | spe-9(hc88)_23_7_98 | - | — | 103.732303732 | — | — | <0.0001 | 15°C vs. 23°C | — | — |
| 235 | w1118_da-GAL4/UAS-dTsc2_9%_yeast_extract_29_24_156 | w1118_+/da-GAL4_9%_yeast_extract_29_12_150 | - | gig overexpression | 100.0 | — | — | <0.0001 | 29°C | — | — |
| 50 | white1118_da>EPCG6783_46_58_72 | white1118_da/+_26_32_64 | - | fabp overexpression | 76.9230769231 | 81.25 | 12.5 | — | — | male | — |
| 49 | white1118_EPCG6783/+_46_70 | white1118_da/+_26_32_64 | - | fabp overexpression | 76.9230769231 | — | 9.375 | — | — | male | — |
| 316 | wild-type_daf-2(RNAi)_20_33_40 | wild-type_20_19_28 | RNAi | daf-2 RNAi | 73.6842105263 | — | 42.8571428571 | — | 20°C | — | — |
| 101 | rpl20b_30_33_36_60_59 | wild-type_30_19_19_33_39 | - | — | 70.7070707071 | 89.4736842105 | 81.8181818182 | — | 30°C | — | — |
| 313 | wild-type_daf-2(RNAi)_20_29_34 | wild-type_20_18_23 | RNAi | daf-2 RNAi | 61.1111111111 | — | 47.8260869565 | — | 20°C | — | — |
| 237 | Oregon_minocycline_11_41 | Oregon_control_7_23 | - | Minocycline treatment | 57.1428571429 | — | 78.2608695652 | <0.0001 | — | female | — |
| 102 | afg3rpl20b_30_30_32_52_40 | wild-type_30_19_19_33_39 | - | — | 53.0303030303 | 68.4210526316 | 57.5757575758 | 0.124 | 30°C | — | — |
| 139 | S288c_WT_44_43_76_40 | S288c_WT_29_29_50_38 | DR | Moderate DR | 51.724137931 | 50.0 | 52.0 | <0.0001 | — | — | — |
| 212 | w1118_da-GAL4/UAS-dTORFRB_72_89_112 | w1118_+/da-GAL4_48_79_133 | - | Dominant negative Tor | 50.0 | — | 12.6582278481 | <0.0001 | — | — | — |
| 94 | sir2;fob1;afg3_30_46_44_78_20 | sir2;fob1_30_30_34_46_20 | - | — | 49.3506493506 | 29.4117647059 | 69.5652173913 | — | 30°C | — | — |
| 96 | sir2;fob1;afg3_30_45_48_67_20 | sir2;fob1_30_30_34_46_20 | DR | — | 47.0779220779 | 41.1764705882 | 45.652173913 | 0.756 | 30°C | — | — |
| 222 | w1118_PO188-GAL4/UAS-dTsc2_35_45_76 | w1118_+/PO188-GAL4_24_28_71 | - | — | 45.8333333333 | — | 60.7142857143 | <0.0001 | — | — | — |
| 136 | S288c_WT_45_45_75_31 | S288c_WT_31_31_50_32 | DR | Moderate DR | 45.1612903226 | 42.8571428571 | 50.0 | <0.0001 | — | — | — |
| 140 | S288c_VMA1(OE)_42_43_75_36 | S288c_WT_29_29_50_38 | - | VMA1 overexpression | 44.8275862069 | 48.275862069 | 50.0 | <0.0001 | — | — | — |
| 314 | mir-239(nDf62)_daf-2(RNAi)_20_26_33 | wild-type_20_18_23 | RNAi | mir-239 mutation | 44.4444444444 | — | 43.4782608696 | — | 20°C | — | — |
| 93 | sir2;fob1;afg3_30_29_30_45_40 | wild-type_30_20_19_38_80 | - | — | 43.3497536946 | 57.8947368421 | 18.4210526316 | 2.95e-05 | 30°C | — | — |
| 326 | Wistar_41_26_58_6 | Wistar_29_22_38_6 | MUT | Olive oil treatment | 41.3793103448 | 18.1818181818 | 52.6315789474 | — | — | male | — |
| 95 | sir2;fob1_30_42_50_64_20 | sir2;fob1_30_30_34_46_20 | DR | — | 39.2857142857 | 47.0588235294 | 39.1304347826 | — | 30°C | — | — |
| 131 | S288c_VMA1(OE)_39_39_80_56 | S288c_WT_28_28_50_50 | - | VMA1 overexpression | 39.2857142857 | 39.2857142857 | 60.0 | 0.0002 | — | — | — |
| 141 | S288c_VMA1(OE)_40_40_64_38 | S288c_WT_29_29_50_38 | DR | VMA1 overexpression | 37.9310344828 | 37.9310344828 | 28.0 | 0.076 | — | — | — |
